IL‐2/IL‐7‐Inducible Factors Pioneer the Path to T Cell Differentiation in Advance of Lineage‐Defining Factors

Scientists showed that IL‐2 signaling was required to maintain open chromatin at hundreds of gene regulatory elements, many of which control subsequent stimulus‐dependent alternative pathways of T cell differentiation.
[EMBO Journal]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Cancer SLC43A2 Alters T Cell Methionine Metabolism and Histone Methylation

Mechanistically, tumor cells avidly consumed methionine and outcompeted T cells for methionine by expressing high levels of the methionine transporter SLC43A2.
[Nature]
Bian, Y., Li, W., Kremer, D. M., Sajjakulnukit, P., Li, S., Crespo, J., Nwosu, Z. C., Zhang, L., Czerwonka, A., Pawłowska, A., Xia, H., Li, J., Liao, P., Yu, J., Vatan, L., Szeliga, W., Wei, S., Grove, S., Liu, J. R., … Zou, W. (2020). Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature, 1–6. https://doi.org/10.1038/s41586-020-2682-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

10,11-Dehydrocurvularin Exerts Antitumor Effect against Human Breast Cancer by Suppressing STAT3 Activation

Scientists showed that 10,11-dehydrocurvularin (2–8 μM) dose-dependently inhibited the proliferation, migration and invasion of human breast cancer cell lines MDA-MB-231 and MDA-MB-468, and induced cell apoptosis.
[acta pharmacologica sinica]
Zhao, Q., Bi, Y., Zhong, J., Li, X., Guo, J., Liu, Y., Pan, L., Tan, Y., Deng, Z., & Yu, X. (2020). 10,11-dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation. Acta Pharmacologica Sinica, 1–10. https://doi.org/10.1038/s41401-020-0499-y Cite
Abstract
Bookmark

No account yet? Register

0
Share

Assessment of STAT5 as a Potential Therapy Target in Enzalutamide-Resistant Prostate Cancer

Isobologram analysis revealed that the signal transducer and activator of transcription (STAT) 5 inhibitor pimozide combined with enzalutamide had additive and synergistic inhibitory effects on cell viability in the used models.
[PLoS One]
Erb, H. H. H., Bodenbender, J., Handle, F., Diehl, T., Donix, L., Tsaur, I., Gleave, M., Haferkamp, A., Huber, J., Fuessel, S., Juengel, E., Culig, Z., & Thomas, C. (2020). Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLOS ONE, 15(8), e0237248. https://doi.org/10.1371/journal.pone.0237248 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Signaling Input from Divergent Pathways Subverts B Cell Transformation

The authors analyzed 1,148 patient-derived B-cell leukemia samples, and found that individual mutations did not promote leukemogenesis unless they converged on one single oncogenic pathway that was characteristic of the differentiation stage of transformed B cells.
[Nature]
Abstract
Bookmark

No account yet? Register

0
Share
Share